Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People who have been diagnosed with a specific type of slow-growing lymphoma called follicular lymphoma (grades 1 to 3a, as classified under current medical guidelines), confirmed by a tissue sample test, and whose lymphoma does not have a particular gene change called an EZH2 mutation
• People whose lymphoma has come back or stopped responding to treatment after at least 3 previous rounds of treatment — including at least one round using a standard antibody therapy targeting a protein called CD20, and at least one round using a newer type of treatment (such as certain targeted therapies or bispecific antibodies)
• People who have previously received radiation therapy (though radiation alone does not count as one of the required prior treatment rounds)
• People who have enough tissue or biological samples available for gene mutation testing
• People who have at least one area of lymphoma large enough to be measured on scans (lymph node larger than 1.5 cm, or a lesion outside lymph nodes larger than 1.0 cm that shows up on a PET scan)
• People with a life expectancy of at least 12 weeks
• People who are generally well enough to carry out light activity and care for themselves (a standard medical fitness score of 0 or 1)
• People whose blood counts, liver, kidneys, and heart function all meet the minimum levels required by the trial (confirm with trial site for specific values)
• Women who could become pregnant must have a negative pregnancy blood test before joining and must agree to use highly effective contraception from the start of the trial until at least 6 months after the last dose
• Men must agree to use effective contraception and not donate sperm from the start of the trial until at least 6 months after the last dose
• People who are willing and able to give written consent and to attend all required trial visits and assessments

Who may not be able to join:

• People with a more aggressive form of follicular lymphoma (grade 3b), mixed or transformed lymphoma, or signs that the lymphoma may be changing into a more aggressive type
• People who have previously received a treatment that targets EZH2 or EZH1/2 (for example, a drug called tazemetostat)
• People with a known allergy or sensitivity to the trial drug or any of its ingredients
• People who have received chemotherapy, immunotherapy, radiation, targeted therapy, or other anti-cancer treatments within approximately 4 weeks before starting the trial; or CAR-T cell therapy within 12 weeks; or a stem cell transplant using their own cells within 3 months
• People who have taken part in another clinical trial using an unapproved treatment within 28 days before starting this trial
• People who have had major surgery within 4 weeks before starting the trial, or who are planning major surgery during the trial
• People who have previously had a stem cell transplant using donor cells, or an organ transplant
• People who are currently taking high-dose steroids (above a low daily threshold) or other medications that suppress the immune system
• People who have recently taken certain medications known to interfere with how the trial drug is processed by the body (confirm with trial site for specific drug names)
• People who have received a live vaccine within 28 days before starting the trial
• People with a history of substance abuse or drug addiction (with a limited exception for people with stable, long-term treatment for insomnia, as assessed by the doctor)
• People who still have significant side effects from previous cancer treatments that have not sufficiently resolved
• People who have had another cancer within the past 3 years, unless it was fully treated and cured — with some exceptions for certain low-risk skin cancers, early-stage cervical or breast changes, superficial bladder cancer, or papillary thyroid cancer
• People whose lymphoma has spread to the brain or spinal cord
• People whose lymphoma has spread to the testicles or breast tissue
• People with a history of a rare immune condition called hemophagocytic lymphohistiocytosis
• People with certain other blood or bone marrow disorders such as immune-related low platelet counts, autoimmune anaemia, or aplastic anaemia
• People with a history of acute myeloid leukaemia (a type of blood cancer)
• People with a history of certain T-cell blood cancers
• People with a history of bone marrow disorders such as myelodysplastic syndrome or related conditions
• People with significant neurological conditions such as epilepsy, stroke (unless fully treated and stable for at least 12 months), dementia, Parkinson's disease, or psychosis
• People with significant heart problems, including a recent heart attack (within 12 months), unstable chest pain, certain types of heart failure, uncontrolled irregular heartbeat, poorly controlled high blood pressure, or abnormal heart rhythm readings on an ECG
• People whose lymphoma is growing into or pressing on vital organs or major blood vessels in a way that creates a risk of bleeding or other serious complications
• People with poorly controlled fluid build-up around the lungs, abdomen, or heart
• People with an unexplained fever above 38°C in the two weeks before starting the trial
• People with a serious active infection that has not been fully treated and cleared
• People with a recent history of tuberculosis (within 1 year), or an older history of active tuberculosis that was not properly treated
• People who test positive for HIV or syphilis (with a limited exception for syphilis considered fully cured by the doctor)
• People who test positive for active hepatitis B or hepatitis C infections
• People who are unable to swallow tablets, or who have significant stomach or bowel conditions that may affect how the drug is absorbed (confirm with trial site)
• People with known bleeding disorders such as haemophilia or von Willebrand disease
• Women who are pregnant or breastfeeding
• People who, for any other reason, are considered by the trial doctor to be unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.